WO2003079976A3 - A substance with sedative effect - Google Patents

A substance with sedative effect Download PDF

Info

Publication number
WO2003079976A3
WO2003079976A3 PCT/US2003/007827 US0307827W WO03079976A3 WO 2003079976 A3 WO2003079976 A3 WO 2003079976A3 US 0307827 W US0307827 W US 0307827W WO 03079976 A3 WO03079976 A3 WO 03079976A3
Authority
WO
WIPO (PCT)
Prior art keywords
substance
patients
acid
days
active ingredient
Prior art date
Application number
PCT/US2003/007827
Other languages
French (fr)
Other versions
WO2003079976A2 (en
Inventor
Boris Vladimirovich Krylov
Boris Fedorovich Shchegolev
Original Assignee
Technology Commercialization
Boris Vladimirovich Krylov
Boris Fedorovich Shchegolev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Technology Commercialization, Boris Vladimirovich Krylov, Boris Fedorovich Shchegolev filed Critical Technology Commercialization
Priority to AU2003220260A priority Critical patent/AU2003220260A1/en
Priority to EP03716557.8A priority patent/EP1485050B1/en
Priority to CA002479214A priority patent/CA2479214A1/en
Publication of WO2003079976A2 publication Critical patent/WO2003079976A2/en
Publication of WO2003079976A3 publication Critical patent/WO2003079976A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy

Abstract

A substance with sedative effect comprises a therapeutically effective amount of a gamma-pyrone such as comenic acid, meconic acid, chelidonic acid, and alike in a pharmaceutically acceptable carrier. When administered at a daily dosage of between 5 and 200 mg of active ingredient per kilogram of a body weight of a patient, the substance can be used to treat various neurotic disorders such as insomnia, anxiety, neurosis, depression as well as withdrawal symptoms for drug addiction patients, especially for patients addicted to opioid-based drugs. The substance can be delivered in a number of ways of systemic administration of a pharmaceutical agent including oral, parenteral, transdermal, and transmucosal administration. For drug addicted patients, the preferred method of administration involves a subcutaneous implant providing a continuous release of an active ingredient at an effective daily rate over the entire treatment period ranging from 5 to 30 days, and preferably from 13 to 20 days.
PCT/US2003/007827 2002-03-19 2003-03-14 A substance with sedative effect WO2003079976A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2003220260A AU2003220260A1 (en) 2002-03-19 2003-03-14 A substance with sedative effect
EP03716557.8A EP1485050B1 (en) 2002-03-19 2003-03-14 A substance with sedative effect
CA002479214A CA2479214A1 (en) 2002-03-19 2003-03-14 A substance with sedative effect

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2002107079/14A RU2209062C1 (en) 2002-03-19 2002-03-19 Substance of sedative action
RU2002107079 2002-03-19

Publications (2)

Publication Number Publication Date
WO2003079976A2 WO2003079976A2 (en) 2003-10-02
WO2003079976A3 true WO2003079976A3 (en) 2004-08-26

Family

ID=28036518

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/007827 WO2003079976A2 (en) 2002-03-19 2003-03-14 A substance with sedative effect

Country Status (6)

Country Link
US (3) US7087640B2 (en)
EP (1) EP1485050B1 (en)
AU (1) AU2003220260A1 (en)
CA (1) CA2479214A1 (en)
RU (1) RU2209062C1 (en)
WO (1) WO2003079976A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8790689B2 (en) * 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
EP2316440A1 (en) 2003-04-30 2011-05-04 Purdue Pharma L.P. Transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer and one fluid communication between the surface of the active agent and the adverse agent
WO2008038160A2 (en) * 2006-07-25 2008-04-03 Technology Commercialization Corp. A substance with sedative effect for use in the treatment of neurotic disorders
AU2010215075B2 (en) * 2009-02-20 2015-08-20 Palmaya Pty Ltd Pharmaceutical preparation and delivery system
RU2477722C1 (en) * 2011-07-27 2013-03-20 Государственное образовательное учреждение высшего профессионального образования "Кубанский государственный университет" (ГОУ ВПО КубГУ) Method for preparing lithium salt of comenic acid and using it as antioxidant, stress- and neuroprotective agent
RU2506078C1 (en) * 2012-08-16 2014-02-10 Федеральное государственное образовательное учреждение высшего профессионального образования "Кубанский государственный университет" (ФГБОУ ВПО "КубГУ") Antioxidant, stress and neuroprotective pharmacological agent sodium comenate
RU2514632C1 (en) * 2012-08-16 2014-04-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный университет" (ФГБОУ ВПО "КубГУ") Antioxidant, stress- and neuroprotective pharmacological agent potassium comenate
RU2561045C1 (en) * 2014-07-15 2015-08-20 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Кубанский государственный университет" (ФГБОУ ВПО "КубГУ") Pharmacological neuroprotective drug
AU2015306075C1 (en) * 2014-08-18 2021-08-26 Electronic Pain Assessment Technologies (epat) Pty Ltd A pain assessment method and system
CN110592805B (en) * 2019-08-31 2021-06-15 福建恒安集团有限公司 Preparation method and application of lily tuber fleeceflower stem sleep-aiding non-woven fabric

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5318739A (en) * 1976-08-03 1978-02-21 Sansho Seiyaku Kk Decolorant for external application
US4221723A (en) * 1976-07-19 1980-09-09 Daiichi Seiyaku Company, Ltd. Method of preparing comenic acid
US4276890A (en) * 1979-04-11 1981-07-07 Fichera Anthony T Tobacco smoking inhibitor
US5219858A (en) * 1990-03-27 1993-06-15 Parnell Pharmaceuticals, Inc. Method and compositions for effecting withdrawal from drug dependency
US5411985A (en) * 1993-05-17 1995-05-02 Merck & Co., Inc. Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 β inventory enzyme

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1796977A (en) 1931-03-17 Sigkjeents
US1782111A (en) 1925-08-04 1930-11-18 Naugatuck Chem Co Method of manufacturing tetra-alkylated thiuramdisulphides
US3797494A (en) 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US3706831A (en) 1971-05-14 1972-12-19 Abbott Lab Method for treatment of drug addiction
US3742951A (en) 1971-08-09 1973-07-03 Alza Corp Bandage for controlled release of vasodilators
US4115567A (en) 1973-12-27 1978-09-19 Carlo Erba S. P. A. 6-Carboxy-2-(2'-pyrazinyl)-chromones and esters thereof
US4115587A (en) * 1976-02-04 1978-09-19 A. H. Robins Company, Inc. Fatty acid amides of norfenfluramine and compositions and methods thereof
US4124715A (en) 1977-05-16 1978-11-07 Jose Pozuelo Method of pharmacologically treating drug addiction with fusaric acid
US4117161A (en) 1977-05-16 1978-09-26 Jose Pozuelo Method of pharmacologically treating drug addiction with alpha-methyl-para-tyrosine
US4221890A (en) 1977-09-30 1980-09-09 Thermal-Chem, Inc. Epoxy resin composition and method for making same
US4198426A (en) 1977-11-28 1980-04-15 Ayerst Mckenna & Harrison Ltd. 2-Substituted-3-methyl-γ-pyrone tricyclic derivatives
US4325952A (en) 1978-04-18 1982-04-20 Aziende Chimiche Riunite Angelini Francesco Method of treating abstinence syndrome with cycloaklyltriazoles
US4311691A (en) * 1979-10-09 1982-01-19 Fichera Anthony T Tobacco smoking inhibitor
GB2128998B (en) 1982-10-22 1986-07-16 Nat Res Dev Pharmaceutical compositions of iron complexes of 3 hydroxy-4-pyrone
US4696818A (en) 1984-03-05 1987-09-29 Kim Tuk M Method of treatment during withdrawl from drug dependency
US4568343A (en) 1984-10-09 1986-02-04 Alza Corporation Skin permeation enhancer compositions
GB8606913D0 (en) * 1986-03-20 1986-04-23 Hider R C Treatment of sickle cell disease
US4786653A (en) 1987-08-24 1988-11-22 Golwyn Daniel H Treatment of neurotransmitter-linked drug abuse
US4788189A (en) 1988-02-29 1988-11-29 Glazer Howard I Method to treat smoking withdrawal symptoms by potentiated central noradrenergic blocking
US6004951A (en) * 1989-11-22 1999-12-21 Bernstein; Lawrence Richard Administration of gallium complexes of 3-hydroxy-4-pyrones to provide physiologically active gallium levels in a mammalian individual
US5646179A (en) 1991-02-08 1997-07-08 Analyticon Gesellschaft Fur Chemische Analytik Und Consulting Gmbh γ-pyrones, γ-pyridones, and γ-thiopyrones, their use as medicaments and process for preparing same
DE4103904C2 (en) 1991-02-08 1995-06-14 Analyticon Ges Fuer Chemische New drugs from gamma-pyrones, gamma-pyridones and gamma-thiopyrones
US5866563A (en) 1991-09-30 1999-02-02 The University Of British Columbia Vanadium compositions
US5298525A (en) 1992-11-23 1994-03-29 University Technologies International, Inc. Diabetes prevention and treatment
US5506268A (en) 1993-06-11 1996-04-09 Nps Pharmaceuticals, Inc. Use of isovaleramide as a mild anxiolytic and sedative agent
US5589182A (en) * 1993-12-06 1996-12-31 Tashiro; Renki Compositions and method of treating cardio-, cerebro-vascular and alzheimer's diseases and depression
ES2230564T3 (en) * 1995-06-10 2005-05-01 Vitra Pharmaceuticals Ltd. FERRIC COMPOUNDS, COMPOSITIONS, METHODS OF MANUFACTURE OF THESE AND ITS USED.
GB9521184D0 (en) * 1995-10-17 1995-12-20 Univ Strathclyde Flavonoids
WO1999007413A1 (en) * 1997-08-11 1999-02-18 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
US6228347B1 (en) * 1997-12-01 2001-05-08 Thione International, Inc. Antioxidant gel for gingival conditions
DE60143857D1 (en) * 2000-03-09 2011-02-24 Univ Yale COMPOSITION COMPRISING PHY906 AND CHEMOTHERAPEUTICS
RU2178303C1 (en) 2000-11-30 2002-01-20 Солагран Лимитед Antioxidant and antiradical agent

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4221723A (en) * 1976-07-19 1980-09-09 Daiichi Seiyaku Company, Ltd. Method of preparing comenic acid
JPS5318739A (en) * 1976-08-03 1978-02-21 Sansho Seiyaku Kk Decolorant for external application
US4276890A (en) * 1979-04-11 1981-07-07 Fichera Anthony T Tobacco smoking inhibitor
US5219858A (en) * 1990-03-27 1993-06-15 Parnell Pharmaceuticals, Inc. Method and compositions for effecting withdrawal from drug dependency
US5411985A (en) * 1993-05-17 1995-05-02 Merck & Co., Inc. Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 β inventory enzyme

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 197814, Derwent World Patents Index; AN 1978-26137A, XP002978567, "Colourless pharmaceutical compsn. for topical application - comprises pyrone cpd. such as kojic acid" *
See also references of EP1485050A4 *

Also Published As

Publication number Publication date
CA2479214A1 (en) 2003-10-02
US20030181516A1 (en) 2003-09-25
US8476314B2 (en) 2013-07-02
EP1485050A2 (en) 2004-12-15
US20120232136A1 (en) 2012-09-13
AU2003220260A8 (en) 2003-10-08
EP1485050B1 (en) 2014-05-07
AU2003220260A1 (en) 2003-10-08
RU2209062C1 (en) 2003-07-27
US20060252824A1 (en) 2006-11-09
US7087640B2 (en) 2006-08-08
EP1485050A4 (en) 2008-08-13
WO2003079976A2 (en) 2003-10-02

Similar Documents

Publication Publication Date Title
US6271240B1 (en) Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
US6004970A (en) Smoking cessation treatments using naltrexone and related compounds
US20090042940A1 (en) Methods and compositions using cholinesterase inhibitors
WO2003080022A3 (en) Analgesics for nasal administration
CA2661759A1 (en) Buprenophine-wafer for drug substitution therapy
MXPA96003633A (en) Use of ketamine and device for the nasal and eye administration of ketamine for the management of pain and for detoxification
KR20120008058A (en) Sublingual dexmedetomidine compositions and methods of use thereof
US8987290B2 (en) Use of opioid formulations in needle-less drug delivery devices
US5989582A (en) Administration of ketamine for detoxification and to treat substance addiction, and compositions therefor
WO2003079976A3 (en) A substance with sedative effect
US20150352040A1 (en) Topical peripheral neuro-affective (tpna) therapy
JP5134973B2 (en) Method of treatment with combination of medicines and combination of medicines suitable therefor
JP4173538B2 (en) Nasal and ophthalmic administration of ketamine for pain management and detoxification
JP2003176227A (en) Pharmaceutical composition, method for alleviating tobacco-smoking withdrawal symptom in patient refraining from smoking, and kit for alleviating tobacco- smoking withdrawal symptom in patient
Stanley et al. Novel delivery systems: oral transmucosal and intranasal transmucosal
WO2008038160A3 (en) A substance with sedative effect for use in the treatment of neurotic disorders
RU2004108853A (en) NEW DRUGS AND THEIR APPLICATION
Werner New drugs for improving injury outcome in spinal cord injuries.
Wilken et al. Smoking cessation—part III: pharmacotherapy of smoking cessation
Cashman Routes of administration
Coulehan The Doctor's Wife
Chao Drug Delivery Systems: Possible Applications in the Treatment of Drug Addiction
WO2004050019A3 (en) Method and compositions for treating anxiety
JP2003512293A5 (en)
MXPA97006456A (en) Nasal and eye administration of ketamine to manage pain and to detoxify

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2003716557

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2479214

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2003716557

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP